Tempest Q4 2021 Earnings Report
Key Takeaways
Tempest Therapeutics reported its year-end 2021 financial results, highlighting achievements such as becoming a public company and establishing a collaboration with Roche. The company ended the year with $51.8 million in cash and cash equivalents.
First clinical data presentation planned for ASCO: TPST-1120 Phase 1 monotherapy and combination dose escalation and optimization arms.
TPST-1120 randomized study in first-line HCC patients with partner Roche is ongoing, with initial data expected by YE22/early 2023.
TPST-1495 Phase 1 monotherapy and combination dose escalation and optimization ongoing, with data expected by YE22/early 2023.
First public presentation of preclinical efficacy results of proprietary small molecule TREX1 inhibitors planned for AACR